---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-037428"
form_type: "8-K"
ticker: "SIGA"
cik: "0001010086"
company_name: "SIGA TECHNOLOGIES INC"
filed_at: "2024-08-15T23:59:59+00:00"
generated_at: "2026-05-31T08:56:13.702517+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# SIGA's tecovirimat misses primary endpoint in PALM 007 mpox trial; shows benefit in subgroups

## Summary
- PALM 007 did not meet primary endpoint of statistically significant improvement in time to lesion resolution.
- Tecovirimat showed clinical benefit vs. placebo in patients treated ≤7 days from symptom onset and those with ≥100 lesions.
- Safety profile comparable to placebo; consistent with prior studies over 15 years.
- Four additional randomized trials (STOMP, UNITY, Platinum-CAN, EPOXI) are ongoing.
- Trial hospitalized all patients, which may have reduced measured benefit vs. real-world settings.

## SEC filing metadata
- accession: 0001140361-24-037428
- form_type: 8-K
- ticker: SIGA
- cik: 0001010086
- company_name: SIGA TECHNOLOGIES INC
- filed_at: 2024-08-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1010086/000114036124037428/0001140361-24-037428-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1010086/000114036124037428/ef20034039_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-037428
- JSON: https://secwatch.observer/filing/0001140361-24-037428.json
- Plain text: https://secwatch.observer/filing/0001140361-24-037428.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.